Researchers have found in a new study that patients receiving a combination of metformin and SGLT2 inhibitors experienced a ...

In a trial, sotagliflozin use in patients with diabetes and chronic kidney disease (CKD) was associated with lower risk of ischemic cardiovascular outcomes.

Empagliflozin patent expiration in India leads to affordable treatment for diabetes, heart failure, and kidney disease.

Millions of people worldwide face a serious health risk from a combination of diabetes, high blood pressure, and kidney disease. However, many don't think about it until it's too late.Even then, ...